| |
|
 |
| EXCLUSIVE:Daniel Chain Paves Way to $60 Billion Drug
Ex- Mindset CEO Closes Deal With Wyeth-Elan | | Daniel Chain has licensed patent applications of his ANTISENILIN® technology to Wyeth and Elan for a Phase III Alzheimer’s drug. The technology was retrieved from Mindset after the Jerusalem company collapsed. Wall Street analysts forecast a $60 billion windfall. | | read full article... |
|
|
 |
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
 |
 | Innovative Tooth Container for Drug Delivery
Slow Release Applications for Oral Hygiene | | Calcident has developed an ingenious way to provide slow release delivery.for pharmaceuticals —a tiny container anchored to the teeth. The disposable containers release drugs or breath fresheners at desired intervals for up to 24 hours. Phase I study for oral thrush approved. | | read full article... |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
 |
| Collaborations Fostered at Conference
CEO of Alnylam Closes Deal | | “We already have done a deal with one Israeli company in the RNAi field, Quark, and we are eager to create breakthrough alliances with other leading partners,” said Barry Greene, CEO of Alynlam. | | read full article... |
|
|
|
|
|
| |
|
 |
| Ramot Achieves $6.7 M in 26 Deals
Graduates Include Epix, Brainstorm and Allergica | | “Internal funds aim to help the researchers reach the proof-of-principle stage and usually comprise grants of about $100,000,” said Dr. Yehuda Niv, CEO. | | read full article... |
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
| |
|
top of the page
|
|
